Industry backs biocatalysis for greener manufacturing

Europes largest public-private partnership dedicated to making drug manufacturing more environmentally friendly was launched in November last year. The 26.4 (21.2)-million project, Chemical Manufacturing Methods for the 21st Century, or CHEM21, is part of the EU Innovative Medicines Initiative (IMI)...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2013-02, Vol.31 (2), p.95-96
Main Author: Aldridge, Susan
Format: Article
Language:English
Subjects:
631/154/433
631/61
639/638/224
706/703/253
Agriculture
Biocatalysis
Biochemistry
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Catalysis
Drug Industry - economics
Europe
Green Chemistry Technology - economics
Green products
Green technology
Humans
Life Sciences
Manufacturing
news
Pharmaceutical industry
Physiological aspects
Production processes
Public private partnerships
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Europes largest public-private partnership dedicated to making drug manufacturing more environmentally friendly was launched in November last year. The 26.4 (21.2)-million project, Chemical Manufacturing Methods for the 21st Century, or CHEM21, is part of the EU Innovative Medicines Initiative (IMI) and brings together six pharma companies, five small to medium-sized enterprises (SMEs) and 13 universities acrossEurope. The four-year project aims toinvestigate alternativecatalysts, includingenzymes, and othergreen technologiesthat can be used tomake the manufacture of pharmaceuticals less harmful tothe environment. Agrowing interest inbiocatalysis expertise also led to anagreement signedin October betweenDSM Pharmaceutical Products of Parsippany, New Jersey, and Almac Group of Craigavon, UK, which gives both companies access to one anothers enzyme technologies. Public and political pressure have encouraged both pharma and governments to take an interest in the green agenda (Box 1). Thus, there could be an increasing role for biotechs who have the expertise to supply enzymes and other biology-based technologies that serve the sustainable agenda.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt0213-95